Pullar T, Zoma A A, Madhok R, Hunter J A, Capell H A
Scott Med J. 1985 Jul;30(3):161-3. doi: 10.1177/003693308503000307.
Approximately 30 non-steroidal anti-inflammatory agents are available for the treatment of rheumatoid arthritis. In this study patient acceptability of five such agents (benoxaprofen, fenbufen, feprazone, flurbiprofen, ketoprofen) is compared in groups of 50 patients with rheumatoid arthritis. Less than 40 per cent of patients continued on the prescribed drug for six months. Significantly more patients stopped fenbufen than stopped feprazone, otherwise dropout rates between the groups were similar. The overall efficacy and toxicity of most currently prescribed NSAIDs appear to be similar, and the availability of a surfeit of such agents dilutes clinical experience with any one drug. Despite subsequent events this method failed to differentiate benoxaprofen from the other agents. It would seem likely that this surfeit of similar drugs hinders detection of unusual complications, and impedes satisfactory management of inflammatory rheumatic disorders.
大约有30种非甾体抗炎药可用于治疗类风湿性关节炎。在本研究中，将50名类风湿性关节炎患者分为几组，比较了其中五种此类药物（苯恶洛芬、联苯丁酮酸、非普拉宗、氟比洛芬、酮洛芬）的患者可接受性。不到40%的患者持续服用处方药达六个月。停用联苯丁酮酸的患者明显多于停用非普拉宗的患者，除此之外，各治疗组之间的脱落率相似。目前大多数常用非甾体抗炎药的总体疗效和毒性似乎相似，此类药物过多使得对任何一种药物的临床经验都被稀释。尽管后来出现了一些情况，但该方法未能将苯恶洛芬与其他药物区分开来。似乎这类相似药物过多会妨碍发现异常并发症，并阻碍对炎症性风湿性疾病进行令人满意的治疗。
